Actively Recruiting
Randomized Study Comparing Cabozantinib Versus Dabrafenib and Trametinib Combination in Patients with BRAF V600E Mutated Refractory Differentiated Thyroid Cancer
Led by ECOG-ACRIN Cancer Research Group · Updated on 2026-09-24
264
Participants Needed
307
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates treatment options for patients with differentiated thyroid cancer that does not respond to usual therapies and has a specific mutation called BRAF V600E. The study aims to compare the effects of cabozantinib alone versus a combination of dabrafenib and trametinib in patients whose cancer has progressed after prior treatments. Researchers want to find out which treatment may control cancer growth longer and assess differences in safety and quality of life. Participants are randomly assigned to one of two groups. One group receives dabrafenib twice daily and trametinib once daily in 28-day cycles, while the other group takes cabozantinib once daily in 28-day cycles. Both groups undergo CT scans, blood tests, and may have MRI scans during treatment. If the cancer progresses, participants may switch to the other treatment group. Throughout the study, participants are monitored for cancer progression, response to treatment, overall survival, and side effects. Quality of life is assessed using patient questionnaires. After treatment ends, follow-up visits occur every three months for two years, then every six months up to five years to continue monitoring health and outcomes.
CONDITIONS
Brief Title
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here